marketcap
Facebook
Twitter
Telegram
Report an ErrorQuarterly report 2024-Q3
added 11-07-2024
Oramed Pharmaceuticals Balance Sheet 2011-2024 | ORMP
Annual Balance Sheet Oramed Pharmaceuticals
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-8.45 M | -39.6 M | -27 M | -19.2 M | -3.33 M | -5 M | -3.97 M | -3.91 M | -3.21 M | -1.76 M | -2.27 M | -4.43 M | -1.51 M |
Long Term Debt |
342 K | 647 K | 370 K | - | - | - | - | - | - | - | - | - | - |
Long Term Debt Current |
267 K | 247 K | 130 K | 44 K | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
4.44 M | 4.74 M | 3.84 M | 7.22 M | 9.96 M | 11.7 M | 14.3 M | 13 M | 37 K | 36 K | 31.2 K | 872 K | 161 K |
Total Current Liabilities |
53.2 M | 5.75 M | 7.37 M | 4.54 M | 5.31 M | 4.55 M | 5.16 M | 3.62 M | 1.49 M | 973 K | 498 K | 644 K | - |
Total Liabilities |
- | - | - | 11.8 M | 15.3 M | 16.3 M | 19.5 M | 16.6 M | 1.53 M | 1.01 M | 529 K | 1.52 M | 602 K |
Deferred Revenue |
- | 1.34 M | 2 M | 2.7 M | 2.7 M | 2.45 M | 2.45 M | 2.16 M | 500 K | - | - | - | - |
Retained Earnings |
-158 M | -163 M | -127 M | -92.6 M | -81.1 M | -69.2 M | -56.5 M | -46 M | -35.1 M | -27.8 M | -22.1 M | -17.9 M | -14.5 M |
Total Assets |
221 M | 162 M | 178 M | 44.6 M | 34.7 M | 47.4 M | 38.7 M | 42.8 M | 26.4 M | 21.8 M | 8.66 M | 5.29 M | 4.33 M |
Cash and Cash Equivalents |
9.06 M | 40.5 M | 27.5 M | 19.3 M | 3.33 M | 5 M | 3.97 M | 3.91 M | 3.21 M | 1.76 M | 2.27 M | 4.43 M | 1.51 M |
Book Value |
221 M | 162 M | 178 M | 32.9 M | 19.4 M | 31.1 M | 19.2 M | 26.2 M | 24.8 M | 20.8 M | 8.13 M | 3.78 M | 3.72 M |
Total Shareholders Equity |
164 M | 152 M | 166 M | 32.9 M | 19.4 M | 31.1 M | 19.2 M | 26.2 M | 24.8 M | 20.8 M | 8.13 M | 3.78 M | 3.72 M |
All numbers in USD currency
Quarterly Balance Sheet Oramed Pharmaceuticals
| 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
186 K | 236 K | 272 K | 342 K | 74.6 M | 488 K | 564 K | 647 K | 5.23 M | 7.31 M | 9.23 M | 11.6 M | 12.5 M | 431 K | 11.7 M | 502 K | 31 K | 31 K | 31 K | 60 K | 9.66 M | - | - | - | 11.4 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
4.29 M | 4.34 M | 4.38 M | 4.44 M | 4.49 M | 4.59 M | 4.66 M | 4.74 M | 4.76 M | 2.84 M | 3.68 M | 3.84 M | 4.8 M | 5.55 M | 4.1 M | 7.02 M | 7.22 M | 7.22 M | 7.22 M | 9.34 M | 9.96 M | 9.96 M | 9.96 M | 10.6 M | 11.7 M | 11.7 M | 11.7 M | 13.7 M | 14.3 M | 14.3 M | 14.3 M | 16.2 M | 13 M | 13 M | 13 M | 38 K | 37 K | 37 K | 37 K | 36 K | 36 K | 36 K | 36 K | 31.9 K | 31 K | 31.2 K | 31.2 K | 240 K | 872 K | 872 K | 872 K | 161 K | 161 K | 161 K | 161 K |
Total Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 503 K | 744 K | - | 602 K | 602 K | - |
Deferred Revenue |
- | - | - | - | - | - | - | 1.34 M | 2 M | 2 M | 2 M | 2 M | 2 M | 2.7 M | 2 M | 2.7 M | 2.7 M | 2.7 M | 2.7 M | 2.7 M | 2.7 M | 2.7 M | 2.7 M | 1.13 M | 2.45 M | 2.45 M | 2.45 M | 2.45 M | 2.45 M | 2.45 M | 2.45 M | 2.45 M | 2.16 M | 2.16 M | 2.16 M | - | 500 K | 500 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-166 M | -147 M | -156 M | -158 M | -171 M | -168 M | -166 M | -163 M | -155 M | -147 M | -137 M | -127 M | -115 M | -108 M | -123 M | -98.2 M | -92.6 M | -92.6 M | -92.6 M | -83.6 M | -81.1 M | -81.1 M | -81.1 M | -71 M | -69.2 M | -69.2 M | -69.2 M | -59 M | -56.5 M | -56.5 M | -56.5 M | -48.7 M | -46 M | -46 M | -46 M | -37.4 M | -35.1 M | -35.1 M | -35.1 M | -29.7 M | -27.8 M | -27.8 M | -27.8 M | -23.2 M | -22.1 M | -22.1 M | -22.1 M | -18.9 M | -17.9 M | -17.9 M | -17.9 M | -15 M | -14.5 M | -14.5 M | -14.5 M |
Total Assets |
165 M | 184 M | 204 M | 221 M | 231 M | 156 M | 160 M | 162 M | 164 M | 162 M | 172 M | 178 M | 128 M | 80.5 M | 182 M | 41 M | 44.6 M | 44.6 M | 44.6 M | 31.1 M | 34.7 M | 34.7 M | 34.7 M | 43.6 M | 47.4 M | 47.4 M | 47.4 M | 41.5 M | 38.7 M | 38.7 M | 38.7 M | 44.9 M | 42.8 M | 42.8 M | 42.8 M | 23.9 M | 26.4 M | 26.4 M | 26.4 M | 24.6 M | 21.8 M | 21.8 M | 21.8 M | 8.01 M | 8.66 M | 8.66 M | 8.66 M | 6.82 M | 5.29 M | 5.29 M | 5.29 M | 3.9 M | 4.33 M | 4.33 M | 4.33 M |
Cash and Cash Equivalents |
42.1 M | 10 M | 18.6 M | 9.06 M | 5.47 M | 6.77 M | 24.1 M | 40.5 M | 33.2 M | 29.9 M | 28 M | 27.5 M | 84.4 M | 79.6 M | 33.8 M | 14.9 M | 19.3 M | 19.3 M | 14.9 M | 3.17 M | 3.33 M | 3.33 M | 3.17 M | 3.86 M | 5 M | 5 M | 3.86 M | 1.26 M | 3.97 M | 3.97 M | 1.26 M | 2.29 M | 3.91 M | 3.91 M | 2.29 M | 1.95 M | 3.21 M | 3.21 M | 1.95 M | 6.66 M | 1.76 M | 1.76 M | 6.66 M | 1.37 M | 2.27 M | 2.27 M | 1.37 M | 5.53 M | 4.43 M | 4.43 M | 5.53 M | 1.5 M | 1.51 M | 1.51 M | 1.5 M |
Book Value |
- | - | - | - | - | - | - | 162 M | 164 M | 162 M | 172 M | 178 M | 128 M | 80.5 M | 182 M | 41 M | 44.6 M | 44.6 M | 44.6 M | 31.1 M | 34.7 M | 34.7 M | 34.7 M | 43.6 M | 47.4 M | 47.4 M | 47.4 M | 41.5 M | 38.7 M | 38.7 M | 38.7 M | 44.9 M | 42.8 M | 42.8 M | 42.8 M | 23.9 M | 26.4 M | 26.4 M | 26.4 M | 24.6 M | 21.8 M | 21.8 M | 21.8 M | 8.01 M | 8.66 M | 8.66 M | 8.66 M | 6.82 M | 5.29 M | 4.79 M | 4.55 M | 3.9 M | 3.72 M | 3.72 M | 4.33 M |
Total Shareholders Equity |
156 M | 177 M | 167 M | 164 M | 148 M | 151 M | 150 M | 152 M | 153 M | 153 M | 162 M | 166 M | 123 M | 90.7 M | 170 M | 28.2 M | 32.9 M | 32.9 M | 28.2 M | 17.2 M | 19.4 M | 17.2 M | 17.2 M | 28.9 M | 31.1 M | 31.1 M | 28.9 M | 22.7 M | 19.2 M | 19.2 M | 22.7 M | 24 M | 26.2 M | 26.2 M | 26.2 M | 22.5 M | 24.8 M | 24.8 M | 24.8 M | 23.7 M | 20.8 M | 20.8 M | 20.8 M | 7.31 M | 8.13 M | 8.13 M | 8.13 M | 6.25 M | 3.78 M | 3.78 M | 3.78 M | 3.32 M | 3.72 M | 3.72 M | 3.72 M |
All numbers in USD currency